Anika Therapeutics (NASDAQ:ANIK) Releases Quarterly Earnings Results, Misses Estimates By $0.13 EPS

Anika Therapeutics (NASDAQ:ANIK) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.13), Zacks reports. Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%.

Anika Therapeutics Stock Performance

Shares of NASDAQ:ANIK traded up $0.32 during midday trading on Wednesday, reaching $17.11. 113,756 shares of the company’s stock traded hands, compared to its average volume of 68,233. The company has a fifty day simple moving average of $16.91 and a two-hundred day simple moving average of $19.66. Anika Therapeutics has a 1 year low of $15.40 and a 1 year high of $29.11. The company has a market cap of $250.59 million, a P/E ratio of -2.57 and a beta of 0.95.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.